ORTEXORTEX News
Tracking EMR? Get live short interest, options flow, and signals on ORTEX.Sign up free →
EM
Earnings PreviewEMR

Emerson Options Turn Defensive Ahead of Tuesday Print

By ORTEX News · Edited by , Editor, ORTEX NewsUpdated 2 min readdata as of 1 Aug 2026, 04:01

Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish

ShareXLinkedInReddit
ORTEX chart of Emerson Electric Co. (EMR) share price and short interest (% of free float), three months to July 30, 2026
ORTEX data as of 1 Aug 2026, 04:01

Emerson Electric heads into its August 4 earnings report with options traders notably more cautious than usual, even as short sellers and the borrow market remain relaxed.

The clearest signal ahead of the print is in options positioning. The put/call ratio has climbed to 0.66, more than two standard deviations above its 20-day average of 0.61 — the most defensive reading in that window. That shift has coincided with a gentle bid in the stock itself, which has added 4.7% over the past month to close at $149.82, and is up 1.3% on the week. The hedging demand stands in contrast to an otherwise constructive price trend, suggesting options traders are buying protection into a report rather than expressing outright bearish conviction.

Short interest tells a much calmer story. At roughly 2.2% of the free float, short positioning is low by any measure. It has ticked up around 3.6% week-on-week — a modest increase that brings it back near June levels after a 5.6% decline over the prior month. More tellingly, the borrow market is about as relaxed as it gets: availability runs at approximately 1,592% of short interest, meaning there are far more shares available to lend than there are shorts outstanding. Cost to borrow has fallen 30% over the past week to just 0.39%. There is no squeeze pressure here, and no evidence of a coordinated bearish build ahead of results.

The analyst community is cautiously constructive, though not uniformly so. JP Morgan upgraded Emerson to Overweight on July 17 — the most recent bellwether move — while maintaining a $157 target modestly above the current price. Bernstein initiated at Outperform with a $175 target in June, and RBC sits at $169 Outperform. The mean analyst target across the coverage universe is $163.54, implying around 9% upside from current levels. DA Davidson's neutral initiation at $145 — below where the stock now trades — and Barclays' equal-weight at $144 represent the skeptical fringe. The bull case centers on Emerson's transformation into a pure-play automation company, with Project Beyond targeting a shift toward two-thirds recurring software revenue and projected organic growth of 4-7% annually. Bears point to competitive intensity in industrial automation, geopolitical exposure across global operations, and IP risk as the company's portfolio reshapes.

The most recent earnings reaction offers context worth noting. Emerson's May 2026 print produced a single-day move of roughly 9.3% — a sharp positive reaction. The print before that delivered less than 2% on the day before fading slightly over five days. That asymmetry in outcomes may partly explain why options traders are paying for protection even as the stock drifts higher. Tuesday's report will test whether the automation-led transformation narrative can hold up against the Street's margin and organic growth expectations at a PE near 21.6x trailing earnings.

Against its peers

Shares moved +1.3% over the past week against a median of -0.8% for its closest peers.

Stocks in this article

See the live data behind this article on ORTEX.

Open EMR on ORTEX →

How this article was generated

Generated
1 Aug 2026, 04:11
Data as of
1 Aug 2026, 04:01
Prompt version
v1.0
Data sources
Short interestCost to borrowUtilizationOptions flowEarningsAnalyst consensusInstitutional positioningORTEX Alpha signalsRecent ORTEX notes

ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.